Table 1. Patients characteristics.
| GCT: study set (n=100) | GCT: validation set (n=77) | Non-GCT neoplasms: control group (n=100) | |
|---|---|---|---|
| Median age (range) (years) | 30 (16–63) | 32 (18–62) | 34 (16–63) |
| Median weight (range) (kg) | 73 (47–99) | 72 (54–99) | 71 (40–99) |
| Performance status | |||
| 0 | 76 (76%) | 65 (85%) | 78 (78%) |
| 1 | 17 (17%) | 9 (12%) | 13 (13%) |
| 2 | 6 (6%) | 2 (3%) | 8 (8%) |
| 3 | 1 (1%) | 0 | 1 (1%) |
| Smoking history | 41/65 (63%) | 32/67 (48%) | 37/48 (77%) |
| Histology and tumour site | |||
| GCT | 86 (86%) | 60 (78%) | |
| NSGCT | 14 (14%) | 17 (22%) | |
| Pure seminoma | 86 (86%) | 73 (94%) | |
| Testis | 14 (14%) | 4 (6%) | |
| Extragonadal | |||
| Non-GCT | |||
| Osteosarcoma | 27 | ||
| Lung cancer | 16 | ||
| Gastrointestinal tract cancer | 14 | ||
| Ewing's sarcoma | 13 | ||
| Head and neck cancer | 12 | ||
| Others | 18 | ||
| Stage | |||
| Stage I | 18 (18%) | 7 (9%) | Localised: 43 (43%) |
| Stage II | 42 (42%) | 37 (48%) | Metastases: 57 (57%) |
| Stage III | 40 (40%) | 33 (43%) | |
| Median maximal tumour diameter (range) (mm) | 43 (10–180) | 30 (0–150) | 68 (4–200) |
| Prophylactic anticoagulant therapy | 12 (12%) | 8/76 (11%) | 21/96 (22%) |
| Biology | |||
| Abnormal PT | 5 (5%) | 7/62 (11%) | 5 (5%) |
| Abnormal APTT | 5 (5%) | 45/72 (63%) | 5 (5%) |
| Elevated fibrinogen | 17/22 (77%) | 15/24 (63%) | |
| Elevated LDH | 41/97 (42%) | 20/59 (34%) |
GCT=germ-cell tumours; NSGCT=nonseminous germ-cell tumours; LDH=lactate dehydrogenase; PT=prothrombine time; APTT=activated partial thromboplastin time.